other:Article Title: Lysin-deficient bacteriophages having reduced immunogenicity
Article Snippet: All clinically important strains of Klebsiella, with K. pneumoniae (ATCC phage #23356-B1) being of particular interest; c. All clinically important strains of Shigella, with S. dysenteriae being of particular interest (ATCC phage #11456a-B1); d. All clinically important strains of Salmonella, including S. abortus-equi (ATCC phage #9842-B1), S. typhi (ATCC phage #19937-B1), S. typhimurium (ATCC phage #19585-B1), S. newport (ATCC phage #27869-B1), S. paratyphi-A (ATCC phage #12176-B1), S. paratyphi-B (ATCC phage #19940-B1), S. potsdam (ATCC phage #25957-B2), and S. pollurum (ATCC phage #19945-B1); e. All clinically important strains of Serratia, most notably S. marcescens (ATCC phage #14764-B1) f. All clinically important strains of Yersinia, most notably Y. pestis (ATCC phage #11953-B1) g. All clinically important strains of Enterobacter, most notably E. cloacae (ATCC phage #23355-B1); 2.
Article Title: Incapacitated whole-cell immunogenic bacterial compositions
Article Snippet: All clinically important strains of Klebsiella, with K. pneumoniae (ATCC phage #23356-B 1) being of particular interest; c. All clinically important strains of Shigella, with S. dysenteriae being of particular interest (ATCC phage #11456a-B1); d. All clinically important strains of Salmonella, including S. abortus-equi (ATCC phage #9842-B1), S. typhi (ATCC phage #19937-B1), S. typhimurium (ATCC phage #19585-B1), S. newport (ATCC phage #27869-B1), S. paratyphi-A (ATCC phage #12176-B1), S. paratyphi-B (ATCC phage #19940-B1), S. potsdam (ATCC phage #25957-B2), and S. pollurum (ATCC phage #19945-B1); e. All clinically important strains of Serratia, most notably S. marcescens (ATCC phage #14764-B 1) f. All clinically important strains of Yersinia, most notably Y. pestis (ATCC phage #11953-B1) g. All clinically important strains of Enterobacter, most notably E. cloacae (ATCC phage #23355-B1); 2.
Article Title: Antibacterial therapy with bacteriophage physico-chemically altered by pegylation to delay inactivation by the host defense system
Article Snippet: [Note: For purposes of brevity, in all the following examples of pathogens, the corresponding wild-type phage will be indicated by the following phraseology: “Example of corresponding phage: ______”.] b) All the clinically important strains of Klebsiella, most notably K. pneumoniae [Example of corresponding phage: ATCC phage # 23356-B1]. c) All the clinically important strains of Shigella, most notably S. dysenteriae [Example of corresponding phage: ATCC phage # 11456a-B1]. d) All the clinically important strains of Salmonella, including S. abortus-equi [Example of corresponding phage: ATCC phage # 9842-B1], S. typhi [Example of corresponding phage: ATCC phage # 19937-B1], S. typhimurium [Example of corresponding phage: ATCC phage # 19585-B1], S. newport [Example of corresponding phage: ATCC phage # 27869-B1], S. paratyphi-A [Example of corresponding phage: ATCC phage # 12176-B1], S. paratyphi-B [Example of corresponding phage: ATCC phage # 19940-B1], S. potsdam [Example of corresponding phage: ATCC phage # 25957-B 2], and S. pollurum [Example of corresponding phage: ATCC phage # 19945-B1]. e) All the clinically important strains of Serratia, most notably S. marcescens [Example of corresponding phage: ATCC phage # 14764-B1]. f) All the clinically important strains of Yersinia, most notably Y. pestis [Example of corresponding phage: ATCC phage # 11953-B 1]. g) All the clinically important strains of Enterobacter, most notably E. cloacae [Example of corresponding phage: ATCC phage # 23355-B1].
Article Title: Bacteriophage having multiple host range
Article Snippet: One among a number of candidate wild-type phages against these particular pathogens that could be used as a starting point for the genetic engineering of the present invention would be θK1–5 having ATCC Accession No. # PTA-3495. (Note: For purposes of brevity, in all the following examples of pathogens, the corresponding wild-type phage will be indicated by the following phraseology: “Example of corresponding phage: ______”.) b) All the clinically important strains of Klebsiella, most notably K. pneumoniae (Example of corresponding phage: ATCC phage #23356-B1). c) All the clinically important strains of Shigella, most notably S. dysenteriae (Example of corresponding phage: ATCC phage #11456a-B1). d) All the clinically important strains of Salmonella, including S. abortus-equi (Example of corresponding phage: ATCC phage #9842-B1), S. typhi (Example of corresponding phage: ATCC phage #19937-B1) S. typhimurium (Example of corresponding phage: ATCC phage #19585-B1), S. newport (Example of corresponding phage: ATCC phage #27869-B1), S. paratyphi-A (Example of corresponding phage: ATCC phage #12176-B1), S. paratyphi-B (Example of corresponding phage: ATCC phage #19940-B1), S. potsdam (Example of corresponding phage: ATCC phage #25957-B2), and S. pollurum (Example of corresponding phage: ATCC phage #19945-B1). e) All the clinically important strains of Serratia, most notably S. marcescens (Example of corresponding phage: ATCC phage #14764-B1). f) All the clinically important strains of Yersinia, most notably Y. pestis (Example of corresponding phage: ATCC phage #11953-B1). g) All the clinically important strains of Enterobacter, most notably E. cloacae (Example of corresponding phage: ATCC phage #23355-B1).
|
ATCC is a verified supplier 
ATCC manufactures this product 